Does the HPV Vaccine Cause Ovarian Failure?

The human papillomavirus (HPV) vaccine can protect against cancer-causing forms of this sexually-transmitted infection. Despite that, some families opt to forego giving it to their children for a variety of reasons.

While a common one is the contention that it encourages girls and boys to be more sexually active, some believe that the HPV vaccine can cause ovarian failure in young women.

Despite there being no evidence of this, the claim has helped fuel lower-than-expected turnout rates for HPV vaccination among American schoolchildren.

Teen girl getting HPV vaccine
BURGER/PHANIE / Getty Images

According to a 2019 study in Human Vaccines & Immunotherapeutics, only 37% of children in the United States have completed the multi-dose HPV vaccine series recommended by the Centers for Disease Control and Prevention (CDC).

How the Rumors Began

In 2014, researchers in New South Wales, Australia reported that three girls, ages 16 to 18, experienced ovarian failure after receiving the quadrivalent HPV vaccine.

The girls, who were unrelated and lived in different parts of the state, had each been given oral contraceptives to treat menstrual cycle abnormalities prior to their diagnosis. The only other commonality the researchers could find was HPV vaccination, which they suggested preceded the ovarian decline.

The researchers even went so far as to suggest that "postmarketing surveillance (of a vaccine) does not accurately represent diagnoses in adverse events."

The suggestions were met with almost immediate criticism. Focusing on three isolated cases without a full investigation of other possible causes was met with criticism because they had focused on the HPV vaccine only without looking into other potential factors. Moreover, no such association had ever been noted in national surveillance despite 80% of girls and 76% of boys in Australia vaccinated against HPV.

Even so, anti-vaccine advocates were quick to leap on the report and circulate it through social media as "proof" of HPV vaccination harm.

What the Research Shows

Ovarian failure is not seen to be a potential risk of HPV vaccination.

A 2018 review published in the journal Pediatrics found the claim had no backing and reported that, of 199,078 females who received the HPV vaccine, only one experienced ovarian failure. Other incidents were excluded because underlying causes of ovarian failure were found.

Likewise, a 2020 review of data from the 2013-2016 National Health and Nutrition Examination Survey noted that there was "no evidence of increased infertility among women who received the HPV vaccine."

The HPV vaccine actually has the potential to enhance female fertility by helping women avoid cancer treatments that can affect their ability to ovulate and conceive.

For the vast majority of adolescents, the worst side effect is a sore arm and headache. Fainting has also been known to occur. On very rare occasions, a serious whole-body allergy (known as anaphylaxis) has been reported following vaccination.

Pre-Approval Testing

It is easy to get swept up by the panic about drug safety. After all, there have been drugs approved by the Food and Drug Administration (FDA) that have been shown in later years to be unsafe. With that said, the process of approval is a long and thorough one.

Before a vaccine is allowed to be administered for widespread use in the United States, it first has to go through a series of rigorous tests in humans. During these pre-licensure clinical trials, the vaccine is tested in thousands of people to assess not only its efficacy but its safety.

This involves blinded research in which participants are randomly selected to receive either the vaccine or a placebo. By comparing the results between both groups, scientists are able to get a clear idea of the benefits and risks of the vaccine.

If, and only if, the vaccine is shown to have strong benefits and minimal risks can it be approved by the FDA for use in the United States. Getting to this point can take years; many vaccine candidates never make it this far.

Monitoring for Safety

Once a vaccine has been licensed, a group within the CDC called the Advisory Committee on Immunization Practices (ACIP) makes recommendations on who should receive it.

Researchers, meanwhile, continue to verify that the vaccine is safe. Through systems like the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety DataLink, the CDC can collect and analyze data on adverse events. If any concerning patterns emerge, the ACIP reviews the findings and adjusts their recommendations accordingly, if needed.

In the case of the HPV vaccine, thousands of people from around the world were included in the pre-market trials, while hundreds of thousands have been included in post-market studies. Research continues to show that the HPV vaccine is overwhelmingly safe and effective at reducing cancer-causing HPV infections.

HPV Vaccination Recommendations

Roughly nine in 10 people in the United States will get HPV at least once in their lifetime. While most infections will clear with no long-term consequences, a small handful of people will go on to develop cancer. Experts have identified several strains of HPV that are more likely to cause cancer and that information was used in creation of the vaccine.

Cervical cancer is the most well-known cancer associated with HPV infection, but HPV can cause at least six other kinds of cancer in both men and women (including anal, penile, vaginal, vulvar, and head and neck cancers). In fact, HPV is believed to be linked to 5% of all cancers worldwide.

CDC Recommendations

The CDC and ACIP recommend HPV vaccination in the following groups:

Although the CDC does not recommend vaccination for everyone over the age of 26, people ages 27 to 45 can decide to get vaccinated based on consultation with their doctors.

The HPV vaccine is administered in two or three doses, depending on when you start the series. Younger adolescents need only two doses, while those who start at age 15 or older (or who are immunocompromised) will need to get three.

Why Vaccinate So Young?

HPV vaccination is the best means to protect against high-risk subtypes of the virus.

Early adolescence is the best time to get vaccinated for several reasons:

  • Because the vaccine can only protect against HPV types the body hasn't yet encountered, it is best to complete the series before most adolescents are sexually active.
  • The vaccine produces a stronger immune response at a younger age compared to older ages.
  • Adolescents are already receiving vaccines against diseases, including meningitis and tetanus, at ages 11 and 12. It makes practical sense to give the HPV vaccine at the same time.

A Word From Verywell 

The benefits of HPV vaccination—preventing cancer and reducing the risk of HPV transmission—overwhelmingly outweigh the risks. Talk to your child's doctor about getting the HPV vaccine at age 11 or 12 in order to best protect them from potential disease.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019;15(1):146-55. doi:10.1080/21645515.2018.1512453

  2. Little DT, Ward HR. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Rep. 2014;2(4):2324709614556129. doi:10.1177/2324709614556129

  3. Dyda A, Shah Z, SurianD. HPV vaccine coverage in Australia and associations with HPV vaccine information exposure among Australian Twitter users. Hum Vaccin Immunother. 2019;15(7-8):1488-95. doi:10.1080/21645515.2019.1596712

  4. Naleway AL, Mittendorf KF, Irving SA, et al. Primary ovarian insufficiency and adolescent vaccination. Pediatrics. 2018;142(3):e20180943. doi:10.1542/peds.2018-0943

  5. Schmuhl N, Mooney K, Zhang X, Cooney L, Conway J, LoConte N. No association between HPV vaccination and infertility in U.S. females 18–33 years oldVaccine. 2020;38(24):4038-4043. doi:10.1016/j.vaccine.2020.03.035

  6. Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 2016;126(1):5-11. doi:10.1172/JCI85446

  7. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2018. Updated October 7, 2019.

  8. De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-70. doi:10.1002/ijc.30716

  9. Centers for Disease Control and Prevention. Human papillomavirus (HPV): vaccinating boys and girls. Updated August 15, 2019.

  10. American Cancer Society. HPV vaccines. Updated July 21, 2020.

  11. Centers for Disease Control and Prevention. Table 1. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Updated February 12, 2021.

  12. MacCosham A, El-Zein M, Burchell AN, et al. Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couplesBMJ Open. 2020;10:e039383. doi:10.1136/bmjopen-2020-039383